A detailed history of Vanguard Group Inc transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 14,516,652 shares of ADMA stock, worth $281 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,516,652
Previous 12,689,394 14.4%
Holding current value
$281 Million
Previous $83.8 Million 93.79%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.98 - $11.18 $10.9 Million - $20.4 Million
1,827,258 Added 14.4%
14,516,652 $162 Million
Q1 2024

May 10, 2024

SELL
$4.4 - $6.74 $890,916 - $1.36 Million
-202,481 Reduced 1.57%
12,689,394 $83.8 Million
Q4 2023

Feb 14, 2024

BUY
$3.08 - $4.52 $339,354 - $498,013
110,180 Added 0.86%
12,891,875 $58.3 Million
Q3 2023

Nov 14, 2023

BUY
$3.47 - $4.61 $1.17 Million - $1.55 Million
336,190 Added 2.7%
12,781,695 $45.8 Million
Q2 2023

Aug 14, 2023

BUY
$3.12 - $4.22 $1.98 Million - $2.67 Million
633,878 Added 5.37%
12,445,505 $45.9 Million
Q1 2023

May 15, 2023

BUY
$3.01 - $3.87 $2.81 Million - $3.61 Million
932,968 Added 8.58%
11,811,627 $39.1 Million
Q4 2022

Feb 10, 2023

BUY
$2.47 - $3.88 $3.92 Million - $6.16 Million
1,587,960 Added 17.09%
10,878,659 $42.2 Million
Q3 2022

Nov 14, 2022

BUY
$2.03 - $2.86 $508,423 - $716,301
250,455 Added 2.77%
9,290,699 $22.6 Million
Q2 2022

Aug 12, 2022

BUY
$1.43 - $2.2 $1.29 Million - $1.98 Million
901,824 Added 11.08%
9,040,244 $17.9 Million
Q1 2022

May 13, 2022

SELL
$1.28 - $1.83 $442,419 - $632,521
-345,640 Reduced 4.07%
8,138,420 $14.9 Million
Q4 2021

Feb 14, 2022

BUY
$1.09 - $1.66 $3.01 Million - $4.58 Million
2,760,709 Added 48.24%
8,484,060 $12 Million
Q3 2021

Nov 12, 2021

BUY
$1.13 - $1.65 $128,968 - $188,316
114,131 Added 2.03%
5,723,351 $6.47 Million
Q2 2021

Aug 13, 2021

BUY
$1.51 - $2.07 $8.47 Million - $11.6 Million
5,609,220 New
5,609,220 $8.98 Million

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.81B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.